Cyberdyne Care Robotics

What Cyberdyne Care Robotics does

Cyberdyne Care Robotics GmbH, founded in August 2013 in Bochum, Germany, is the European subsidiary of CYBERDYNE INC. (TYO: 7779, Tokyo). It manufactures, distributes, and clinically operates the HAL (Hybrid Assistive Limb) platform — described as the world's first neurologically controlled wearable cyborg — built on the company's proprietary Cybernics technology that merges human, robotic, and information systems. The flagship medical devices include HAL Lower Limb (HAL-ML05) and HAL Single Joint (HAL-MS01), both CE-marked (CE 0197) for neurological rehabilitation of patients with spinal cord injuries, stroke, cerebral palsy, and progressive neuromuscular diseases; the non-medical HAL Lumbar Type supports back care for caregivers and elderly users; and the pediatric HAL for Child / HAL 2S covers smaller body sizes. Adjacent products include CYIN (communication interface for neurodegenerative patients), ACOUSTIC X (LED-based photoacoustic-ultrasound imaging), PARO therapeutic robot, and a self-driving cleaning robot. The underlying interactive BioFeedback (iBF) principle detects bioelectric signals from the central nervous system at the skin surface, activates motors to support intended movement, and closes a proprioceptive loop with the brain — distinct from passive exoskeletons that mechanically move the patient.

The company's revenue mechanics combine direct therapy services at its in-house ZNB (Zentrum für neurorobotales Bewegungstraining) in cooperation with Bergmannsheil University Hospital, European-wide HAL device rental and sale, and insurance reimbursement flows from German workers' compensation (Berufsgenossenschaft) and select private insurers (e.g., Nürnberger Versicherungen). Distribution is enterprise-direct in Europe, complemented by international deployments including a major PERKESO-led installation in Malaysia (114 HAL units across 12 facilities as of March 2024 with an additional 65-unit center planned). The go-to-market leans heavily on medical trade fairs (MEDICA, REHACARE, ALTENPFLEGE, Pro Care, DGN/DGNKN/DGNC congresses), scientific publications, and physician referrals, with a stated strategy to broaden German statutory coverage via the G-BA Erprobung process under §137e SGB V. Validation is anchored in a June 2025 Global Spine Journal systematic review identifying HAL as the only exoskeleton (among 10 devices) to consistently induce neuroplasticity and a 2025 University of Tsukuba fNIRS study demonstrating brain-level activation specific to HAL's voluntary-movement approach. Revenue and headcount are not disclosed for the German entity.

Name

Cyberdyne Care Robotics

Legal name

Cyberdyne Care Robotics GmbH

Website

https://cyberdyne.eu

Company type

Private

Founded year

2013

Operating status

Operating

Short description

Cyberdyne Care Robotics GmbH, based in Bochum, Germany, is the European subsidiary of CYBERDYNE INC. (Japan). It manufactures and clinically deploys the HAL (Hybrid Assistive Limb) wearable cyborg platform, providing CE-marked neurorehabilitation devices and therapy services to patients with spinal cord injuries, stroke, cerebral palsy, and neuromuscular diseases across European hospitals and rehabilitation centers.

Ownership category

akta.pro rank

Product category

Neurorehabilitation Robotics

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)

akta.pro primary industry

Healthcare & Assistive Robotics (HDAAAIAC)

akta.pro secondary industry

Robot Hardware, Actuators & Components (sensors, grippers, motors) (HDAAAIAL)

Keywords

• Neurorehabilitation robotics
• Wearable medical robots
• Rehabilitation medical devices
• Cybernics technology
• Neurological therapy systems

Headquarters

HQ city

Bochum

HQ country

Germany

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. HAL Therapy Services: The company directly provides HAL-based neuromuscular feedback therapy at its ZNB (Zentrum für neurorobotales Bewegungstraining) facility in Bochum, in cooperation with Bergmannsheil University Hospital. Therapy is provided to patients with spinal cord injuries, stroke, cerebral palsy, ALS, and progressive neuromuscular diseases.
2. HAL Product Rental and Sales: The company rents and sells HAL systems (including Lower Limb, Single Joint, and Lumbar Type) across Europe from its European headquarters. Rental and sale of medical and non-medical HAL devices constitutes a major revenue stream.
3. Insurance Reimbursement: HAL therapy costs are covered for patients insured through Berufsgenossenschaft (workers' compensation) or private insurance providers such as Nürnberger Versicherungen. The company also pursues G-BA (Federal Joint Committee) testing approval under § 137e SGB V to enable broader statutory health insurance coverage in Germany.

Go-to-market motion2 records

Distribution channels5 records

Marketing channels6 records

Core offering

Cyberdyne Care Robotics GmbH manufactures and distributes the HAL (Hybrid Assistive Limb) wearable cyborg family of medical and non-medical devices for neurorehabilitation, and delivers HAL-based neuromuscular feedback therapy services at its ZNB center in Bochum. The company's core technology uses interactive BioFeedback (iBF) to detect bioelectric signals from the central nervous system and provide synchronized robotic support that promotes neuroplasticity in patients with spinal cord injuries, stroke, and progressive neuromuscular diseases.

Product overview

Cyberdyne Care Robotics offers the HAL (Hybrid Assistive Limb) platform - the world's first neurologically controlled wearable cyborg system. The portfolio includes medical devices (HAL Lower Limb for full lower limb support, HAL Single Joint for targeted joint therapy, HAL Motion Principle core technology) and non-medical products (HAL Lumbar Type for back support). Supporting products include CYIN communication device and ACOUSTIC X photoacoustic imaging system. The company provides HAL Treatment neurorehabilitation therapy services at its Zentrum für neurorobotales Bewegungstraining (ZNB), and Neuro HALFIT wellness programs. The iBF (interactive BioFeedback) technology platform forms the foundation, detecting bioelectric signals from the nervous system and translating movement intention into robotic support to promote neuroplasticity and functional improvement.

Differentiator

Problem solved

Functional benefit

Brands

• HAL (Hybrid Assistive Limb): The world's first neurologically controlled wearable cyborg for neurorehabilitation, used for treatment of spinal cord injuries, stroke, and neuromuscular diseases.
• Neuro HALFIT
• ZNB (Zentrum für neurorobotales Bewegungstraining)
• CYIN
• Acoustic X
• PARO

Products and services

• HAL Lower Limb (HAL-ML05) Medical device (CE 0197) — neurologically controlled wearable cyborg for patients with spinal cord injuries, stroke, traumatic brain injuries, and progressive neuromuscular diseases. Supports hip and knee joints of both legs via four sensor sets detecting bioelectric signals from flexor and extensor muscles, enabling voluntary movement of paralyzed legs. Bilateral model weighs 14 kg; single-leg model 9 kg; battery life approximately 1 hour.
• HAL Single Joint (HAL-MS01) Portable, lightweight CE-marked medical device for intensive repeated training of specific joints such as elbow, knee, and ankle. Can be used in early recovery phase after surgery, in bed, or at home. Displays bioelectric signal strength and exercise targets via a dedicated HAL Monitor. Weight approximately 1.5 kg; battery life approximately 120 minutes.
• HAL Lumbar Type Non-medical wearable assistive system supporting the lower back for caregivers, industrial workers, and elderly individuals. Reduces physical strain during patient transfers, bathing, dressing, repositioning, and lifting heavy objects. Also used in the Neuro HAL Plus athletic training program to optimize muscle contraction-relaxation timing.
• HAL 2S / HAL for Child (Small-Size HAL) Specialized pediatric version of HAL Lower Limb optimized for children and smaller individuals with body heights of 100–150 cm. FDA cleared (May 2024), CE marked (December 2024), and Japan approved (January 31, 2025). Indicated for spinal cord injuries, cerebral palsy, multiple sclerosis, traumatic brain injuries, ALS, and other conditions; intended for clinical use with typical 30–60 treatment sessions supervised by physiotherapists.
• Acoustic X World's first LED-based plug-and-play multispectral handheld device combining photoacoustic and ultrasonic imaging for clinical research. Real-time in vivo visualization of absorbers including capillaries and oxygen saturation differences through light absorption and ultrasound information.
• CYIN Communication interface that uses biological information to simplify communication for people including those with progressive neurodegenerative diseases, regardless of physical limitations.
• Self-driving Cleaning Robot (Reinigungsroboter) Self-driving cleaning robot for large facilities such as airports, shopping centers, hotels, and conference centers. Cleans spaces autonomously without human support.
• HAL Treatment (Neurorehabilitation Therapy Service) Direct HAL-based neurorehabilitation therapy service delivered at the ZNB center in Bochum in cooperation with Bergmannsheil University Hospital. Treats patients with cerebrovascular diseases, spinal cord injuries, and progressive neuromuscular diseases using neuromuscular feedback training to promote neural reconnection and improve locomotor function. Covered by Berufsgenossenschaft (workers' compensation) and private insurers such as Nürnberger Versicherungen.
• Neuro HALFIT Neurological fitness program using HAL Lumbar Type to promote movement well-being and mobility for elderly individuals. Trains the nervous system on correct movement execution to improve muscle flexibility, muscle strength, and movement control.
• MTX Neuro HAL Plus Athletic training program using HAL Lumbar Type that improves muscle performance and establishes optimal timing and balance of muscle contraction and relaxation through visual biofeedback on muscle tension. Available only in Japan via the parent CYBERDYNE INC.; introduced publicly with the Shizuoka Bluerevs professional rugby team in December 2021.
• PARO Therapeutic Robot Seal Therapeutic robot seal used as a complement to non-pharmacological approaches in dementia care, palliative care, and for children with developmental disorders. Helps counteract cognitive decline and depression, facilitates interaction between patients and caregivers, and reduces anxiety and stress. Distributed by Cyberdyne Care Robotics.

Quantifiable outcome

• 10.066% improvement in 2-minute walk test distance with HAL vs hoist-only treatment in patients with slowly progressive rare neuromuscular diseases (p=0.0369, 95% CI: 0.667–19.464)
• +6 more outcomes

Named customers6 records

Segments5 records

Ideal customer profiles5 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature8 records

Partnerships

Seven partnerships are on record, tiered core, flagship and minor.

• PERKESO (Social Security Organization, Malaysia)coreStrategic or Co-development Partner · 23 May 2024CYBERDYNE Inc. and PERKESO have partnered since 2018 to deploy HAL technology in Malaysia's public social security system. As of March 31, 2024, 114 HAL units operate across 12 facilities, providing free Cybernics treatment to patients. A new PERKESO National Neuro-Robotics and Cybernics Rehabilitation Centre in Perak Ipoh (scheduled to open end 2024) will receive 50 sets comprising 65 units, making it the largest single-facility installation globally.
• Bergmannsheil University Hospital (Bochum)coreStrategic or Co-development PartnerThe ZNB (Zentrum für neurorobotales Bewegungstraining) operates in clinical cooperation with the Surgical University Clinic at Bergmannsheil. This partnership enables HAL therapy services and integrates research with clinical care. Prof. Dr. Schildhauer from Bergmannsheil presented experiences with robot-assisted rehabilitation at the Hannover Cybernics & Neurobionics Summit 2024.
• University of Tsukuba / University of Tsukuba HospitalcoreStrategic or Co-development PartnerOngoing research collaboration including a multicenter randomized controlled trial (NCY-3001) for neuromuscular diseases, a cerebral palsy clinical trial initiated January 2022, and a groundbreaking fNIRS brain imaging study published in 2025 demonstrating HAL's effect on brain plasticity. The hospital has >2,600 staff and serves as the base for Prof. Dr. Yoshiyuki Sankai's Center for Cybernics Research.
• AMED (Japan Agency for Medical Research and Development)flagshipGTM or Marketing PartnerAMED invited Cyberdyne to exhibit at their booth at MEDICA 2024 in Düsseldorf, providing access to a premier international medical technology trade fair. This partnership supports CYBERDYNE's international market development.
• Centro San Girolamo (Italy)minorChannel Partner/ Reseller/ DistributorItalian neurorehabilitation center founded by Francesco Chiampo (2013), specializing in HAL-based therapy. Centro San Girolamo has been a long-term partner demonstrating HAL therapy outcomes, including patient recovery stories presented at TEDxMantova.
• Shizuoka Bluerevs (Japan Rugby League One)minorOthersProfessional rugby team signed contract with CYBERDYNE Inc. in December 2021 to use MTX Neuro HAL Plus training program with HAL Lumbar Type for athletic performance optimization. Players demonstrated the technology at a press conference and public demonstration at Yamaha Motor Okubo Ground.
• Niigata National Hospital (Japan)minorStrategic or Co-development PartnerDr. Takashi Nakajima's hospital conducted Cybernics treatment for ALS patients, demonstrating 25% average improvement in 2-minute walking distance. Results published in Yomiuri Shimbun (world's largest circulation newspaper), supporting clinical evidence base for HAL efficacy.

Scale indicators6 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Hocoma (DIH Medical): Hocoma, now part of DIH Medical, produces Lokomat — a robotic gait-therapy treadmill system that was named alongside HAL in the 2025 systematic review. Both companies sell into the same hospital and rehabilitation-center budgets for gait therapy, with Hocoma offering a stationary treadmill-based alternative versus HAL's wearable exoskeleton.
• Ekso Bionics: Ekso Bionics (now Ekso Health) develops the EksoGT and EksoNR exoskeletons for spinal cord injury, stroke, and acquired brain injury rehabilitation. Ekso is one of the named competitors in the systematic review that found HAL uniquely induced neuroplasticity, making it the most direct clinical-evidence benchmark for HAL Lower Limb in inpatient rehabilitation.
• Wandercraft: Wandercraft develops the Atalante X self-balancing lower-limb exoskeleton for spinal cord injury and stroke rehabilitation. Founded in France and competing directly in European neurorehabilitation, Wandercraft targets similar inpatient and outpatient settings as HAL Lower Limb with a different mechanical self-balancing approach.
• Parker Hannifin (Indego): Parker Hannifin's Indego is a modular lower-limb exoskeleton for spinal cord injury and stroke rehabilitation. Indego competes with HAL Lower Limb in the same patient indications and hospital channels, and was one of the exoskeleton devices benchmarked in the 2025 systematic review.
• ReWalk Robotics: ReWalk Robotics is a direct competitor in lower-limb exoskeletons for spinal cord injury and stroke rehabilitation. ReWalk Personal 6.0 and ReWalk Restore compete head-to-head with HAL Lower Limb in the same European hospital channel, and ReWalk was one of the nine devices benchmarked against HAL in the 2025 Global Spine Journal systematic review.

Emerging players

• Tyromotion: Tyromotion is an Austrian developer of robotic and sensor-based rehabilitation devices for upper-limb and cognitive therapy (e.g., Armeo, Pablo). It serves the same European hospital and rehabilitation-center accounts as Cyberdyne Care Robotics and overlaps with HAL Single Joint in targeted joint-therapy use cases.
• Fourier Intelligence: Fourier Intelligence develops the ExoMotus lower-limb exoskeleton for stroke and spinal cord injury rehabilitation, primarily in the Asian market with growing European presence. It competes with HAL in the same clinical indications and increasingly in European distribution channels as Fourier expands internationally.
• Bionik Laboratories: Bionik Laboratories develops the InMotion ARM and InMotion HAND robotic systems for upper-limb neurorehabilitation, addressing stroke and other neurological conditions. While Bionik focuses on upper-extremity rather than HAL's lower-limb primary use, both compete for the same hospital rehabilitation capital budgets.
• Rex Bionics: Rex Bionics develops the REX hands-free self-supporting exoskeleton for rehabilitation and mobility assistance. While REX uses a different mechanical approach (no crutches required), it targets overlapping patient populations (SCI, stroke, MS) in the same European rehabilitation-center channel.

Broad incumbents

• Ottobock: Ottobock is a global incumbent in prosthetics, orthotics, and exoskeletons (including C-Brace and Paexo) that competes with HAL on hospital and rehabilitation budgets. Unlike HAL's specialized Cybernics platform, Ottobock offers a broad portfolio spanning prosthetic limbs, wheelchairs, and industrial exoskeletons to the same customer base.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cyberdyne Care Robotics